Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

Also called NCT06723002

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06723002
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06723002. Randomized; double masking; primary purpose treatment. Start 2024-12-01 (anticipated); primary completion 2025-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Olive Leaf Extracts on Endothelial Dysfunction in Patients With Acute Coronary Syndrome
Acronym
ACS_ATHEROLIV
Condition
Acute Coronary Syndrome (ACS)
Condition
Reactive Hyperemia
Condition
Endothelial Dysfunction
Intervention (Drug)
Atherolive 500mg/day
Intervention (Drug)
Atherolive 1000/day
Intervention (Drug)
Placbo_Atherolive
Lead sponsor
University of Monastir (class: other)

Record details

Record id
cardio:ct-nct06723002
Content hash
d8066097093ee7275f1bde3b963fff582a2c397bef20e4c2f9b2e19de2582761